Estela Rodriguez, Associate Director of Community Outreach- Thoracic Oncology at Sylvester Comprehensive Cancer Center, shared on X:
“More great news for patients with rare mutations: FDA Oncology approved Sunvozertinib (Zegfrovy) oral TKI for EGFR 20ins lung cancer after platinum chemo: a big area of unmet need.
- WU-KONG1B trial
- 200mg once a day
- ORR 46% DOR 11.1 mos
- AEs: Diarrhea (17%), CPK levels (11%), and anemia (3.6%) ILD, ocular tox.”
More posts featuring Estelamari Rodriguez.